Highlights
1 patentProfile claimed by owner
About
Oral drug for treating cardio-metabolic disease and rare MSUD
Ramino Bio is developing an oral drug to treat cardio-metabolic diseases and rare Maple Syrup Urine Disease (MSUD). Ramino Bio’s unique technology addresses the unmet need of several metabolic diseases in the emerging novel elevated BCAA (Branched-chain amino acid) field. With a druggable lead compound, showing efficacy in-vivo, Ramino Bio is heading preclinical stages. First-in-human studies are planned within 18 months with our lead candidate. We are committed to developing effective therapies for the benefit of the patients.
Identity
| Name | Ramino-Bio |
|---|---|
| Slug | ramino-bio |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoPW1rIQKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Nov 2025 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | |
| HQ address | Ilan Ramon St 2, Ness Ziyyona, Israel |
Web & social
| https://www.linkedin.com/company/93388496 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Materials & Substances
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
rare-diseasesbiopharmaceuticaltreatmentspharmaceuticalsmetabolic-diseasedrug-developmentcardiovascularbiotechnology
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}